Belmont, MANCT07758010Now EnrollingIRB Ready

Depressive Disorder, Treatment-Resistant Clinical Trial in Belmont, MA

Access cutting-edge depressive disorder, treatment-resistant treatment through this clinical trial at a research site in Belmont. Study-provided care at no cost to qualified participants.

Sponsored by Mclean Hospital

Quick Self-Assessment

See if you qualify for this Belmont location

Preparing your pre-screening questions…

Expert Care in Belmont

Access depressive disorder, treatment-resistant specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related depressive disorder, treatment-resistant treatment provided free

Apply for This Belmont Location

Check if you qualify for this depressive disorder, treatment-resistant clinical trial in Belmont, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Belmont

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Belmont site if eligible
  4. 4Begin participation

About This Depressive Disorder, Treatment-Resistant Study in Belmont

The goal of this clinical trial is to learn whether two forms of one-day accelerated transcranial magnetic stimulation (TMS) can reduce depressive symptoms in adults with treatment-resistant depression. Treatment-resistant depression is depression that has not improved enough after at least two adequate antidepressant medication treatments. TMS is a non-invasive treatment that uses magnetic pulses to stimulate specific areas of the brain. The main questions this study aims to answer are: * Does continuous theta-burst stimulation (cTBS) targeting the precuneus reduce depressive symptoms 4 weeks after treatment compared with sham stimulation? * Does intermittent theta-burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex reduce depressive symptoms 4 weeks after treatment compared with sham stimulation? Researchers will compare precuneus cTBS, left dorsolateral prefrontal cortex iTBS, and sham stimulation to determine whether either active treatment reduces depressive symptoms more than sham stimulation. Participants will be randomly assigned to one of the three groups and will not be told which treatment they initially receive. Participants will: * Complete screening procedures and baseline assessments of depression, rumination, and cognitive function * Receive 20 sessions of active or sham TMS during one in-person study day * Complete follow-up assessments 1, 2, 3, and 4 weeks after the intervention * Report any side effects or medical problems experienced during the study Participants initially assigned to sham stimulation may choose to receive active TMS after completing the 4-week follow-up period. Those who choose this option will receive either precuneus cTBS or left dorsolateral prefrontal cortex iTBS and will complete additional follow-up assessments.

Sponsor: Mclean Hospital

Who Can Participate

Inclusion Criteria

Age 18 years or older.
Able to speak, read, and understand English sufficiently to complete the study assessments and provide informed consent independently.
Diagnosis of major depressive disorder according to DSM-5-TR criteria, confirmed by a qualified physician.
Treatment-resistant depression, defined as an inadequate response to at least two adequate trials of antidepressant pharmacotherapy.
Patient Health Questionnaire-9 (PHQ-9) total score of 10 or higher.

Exclusion Criteria

Any condition identified through TMS safety screening that, in the judgment of a study physician, presents an unacceptable safety risk for TMS. Such conditions may include:
A history of a serious adverse reaction during TMS treatment.
A history of seizure.
A history of stroke.
A history of serious head injury or neurosurgery.
Metal in the head outside the mouth, such as shrapnel, surgical clips, or metal fragments.
An implanted device, such as a cardiac pacemaker, cochlear implant, medical pump, or intracardiac line.
Frequent or severe headaches.
Another brain-related condition or an illness that caused brain injury.
A family history of epilepsy.
Permanent tattoos on the head or neck.
Current recreational drug use.
Current pregnancy or possible pregnancy.
Use of a medication or combination of medications, a recent medication change, or medication withdrawal that, in the judgment of a study physician, presents an unacceptable safety risk, including a clinically significant increase in seizure risk.
Current or lifetime diagnosis of bipolar I disorder, bipolar II disorder, a schizophrenia spectrum disorder, or another primary psychotic disorder.
Active suicidal ideation with intent or plan requiring immediate clinical intervention, or another acute safety concern that cannot be safely managed within the study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Belmont?

Yes, this clinical trial (NCT07758010) has an active research site in Belmont, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Depressive Disorder, Treatment-Resistant Treatment Options in Belmont, MA

If you're searching for depressive disorder, treatment-resistant treatment options in Belmont, MA, this clinical trial (NCT07758010) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Belmont research site is actively enrolling participants for this clinical trial. You'll receive care from experienced depressive disorder, treatment-resistant specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all depressive disorder, treatment-resistant clinical trials near you to find additional studies recruiting in your area.

More Myalgic Encephalomyelitis Trials in Belmont, MA

See all myalgic encephalomyelitis clinical trials recruiting in Belmont — not just this study.

Browse Myalgic Encephalomyelitis Trials in Belmont →

Browse More Trials by Condition

Myalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Belmont?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Belmont, MA